Beranda › Kanker Toraks › Florida
Uji klinis Kanker Toraks di Florida
6 studi untuk Kanker Toraks mencari peserta di lokasi di Florida.
Teks studi resmi (Bahasa Inggris)
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Florida Cancer Specialists, Sarasota
- Moffitt Cancer Center and Research Institute, Tampa
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06128551A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
- Site 1009, Plantation
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT07407933A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Millennium Oncology Research Clinic, Hollywood
- University of Florida - Jacksonville, Jacksonville
- Miami Cancer Institute at Baptist Health, Inc., Miami
- dan 3 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06119581A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Memorial Healthcare System, Hollywood
Menerima pesertaFase 1/2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 27 Mei 2026 · NCT03093116Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Moffitt Cancer Center, Tampa
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Mei 2026 · NCT05379985Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
- Bay Pines VA Healthcare System, Pay Pines, FL, Bay Pines
- Miami VA Healthcare System, Miami, FL, Miami
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Feb 2026 · NCT02984761Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.